Katherine Szarama, PhD, Named Acting CBER Director: Who’s Next?

Key Takeaways

• Szarma appointed acting CBER director after Vinny Prasad's departure
• She previously served as CBER deputy director and FDA senior advisor
• Permanent director likely to be external candidate, e.g., Houman Hemmati
• Industry watches for political influence amid vaccine and biologics scrutiny
• CBER's reduced size heightens operational challenges for new leader

Pulse Analysis

The FDA’s Center for Biologics Evaluation and Research (CBER) sits at the nexus of vaccine, blood product and emerging gene‑therapy approvals. Its regulatory decisions affect billions of dollars in R&D spend and shape market entry for biotech firms. A sudden leadership change, therefore, reverberates through product pipelines, investor confidence, and the broader public‑health agenda. Szarama’s appointment as acting director underscores the agency’s need for continuity while it searches for a long‑term steward.

Katherine Szarama brings a blend of scientific expertise and cross‑agency experience. A trained biologist, she previously served as CBER’s deputy director and held senior roles at the Centers for Medicare & Medicaid Services, Emerson Collective and ARPA‑Health. Her brief tenure at the FDA, beginning late last year, equips her with insider knowledge of the center’s operational challenges, yet her acting status signals that the administration is keeping options open for a more politically seasoned leader. This interim period allows the agency to maintain momentum on critical reviews without committing to a permanent policy direction.

Speculation about the permanent CBER chief centers on two prominent candidates: ophthalmologist Houman Hemmati, a frequent Fox News commentator, and epidemiologist Stefan Baral, a Hopkins researcher with COVID‑19 publications. Both bring distinct strengths—media savvy versus academic credibility—but each must navigate a politically charged environment, especially with vaccine hesitancy and high‑profile legal battles looming. The eventual appointment will influence how CBER balances scientific rigor with external pressures, impacting everything from clinical trial timelines to the strategic planning of biotech companies seeking FDA clearance.